Stay tuned for our LIVE OncLive News Network coverage straight from the #ASH18 conference floor! 

Search Videos by Topic or Participant
Browse by Series:

Investigational Approaches in RCC

Panelists: Robert A. Figlin, MD,FACP, Cedars-Sinai; Saby George, MD, FACP, Roswell Park;Sumanta Kumar Pal, MD, City of Hope
Published: Monday, May 25, 2015
Available on iTunes Podcast
For High-Definition, Click
There is limited utility for an mTOR inhibitor in the frontline setting for patients with renal cell carcinoma (RCC), notes Sumanta Kumar Pal, MD. The phase II RECORD-3 study compared sunitinib followed by everolimus to sequential everolimus and sunitinib. Overall, the trial did not demonstrate that first-line everolimus was noninferior to first-line sunitinib.

In the high-risk population, an mTOR inhibitor could be effective, notes Pal. In this situation, he prefers to utilize temsirolimus versus everolimus. At this time, there remains a need for prospective clinical trial data assessing the efficacy of an mTOR inhibitor in the frontline setting for high-risk patients with RCC. 

In addition to frontline mTOR inhibition, there is limited data on the efficacy of neoadjuvant and adjuvant treatment for RCC. Neoadjuvant therapy would ideally be used when there is potential for curing disease prior to its surgical removal, notes Saby George, MD. However, this approach remains largely theoretical. Future trials should focus on tumor shrinkage or the use of nephron-sparing approaches in the setting of neoadjuvant therapy, George suggests.
Slider Left
Slider Right
Available on iTunes Podcast
For High-Definition, Click
There is limited utility for an mTOR inhibitor in the frontline setting for patients with renal cell carcinoma (RCC), notes Sumanta Kumar Pal, MD. The phase II RECORD-3 study compared sunitinib followed by everolimus to sequential everolimus and sunitinib. Overall, the trial did not demonstrate that first-line everolimus was noninferior to first-line sunitinib.

In the high-risk population, an mTOR inhibitor could be effective, notes Pal. In this situation, he prefers to utilize temsirolimus versus everolimus. At this time, there remains a need for prospective clinical trial data assessing the efficacy of an mTOR inhibitor in the frontline setting for high-risk patients with RCC. 

In addition to frontline mTOR inhibition, there is limited data on the efficacy of neoadjuvant and adjuvant treatment for RCC. Neoadjuvant therapy would ideally be used when there is potential for curing disease prior to its surgical removal, notes Saby George, MD. However, this approach remains largely theoretical. Future trials should focus on tumor shrinkage or the use of nephron-sparing approaches in the setting of neoadjuvant therapy, George suggests.
View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: Oncology Best Practice™ Decision Points in Advanced NSCLC: Assessing Treatment Options Beyond Disease ProgressionNov 30, 20181.0
Community Practice Connections™: Precision Medicine for Community Oncologists: Assessing the Role of Tumor-Testing Technologies in Cancer CareNov 30, 20181.0
Publication Bottom Border
Border Publication
x